Arthritic Therapeutic Market Developments And Opportunities Across 2026–2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Arthritic Therapeutic Market Expected To Scale Between 2026 And 2030?

The arthritic therapeutic market has demonstrated robust growth in recent years. It is anticipated to increase from $72.44 billion in 2025 to $77 billion in 2026, at a compound annual growth rate (CAGR) of 6.3%. This historical expansion can be attributed to several factors, including the increasing global prevalence of arthritis, an expanding geriatric population, restricted access to advanced therapeutics, a heightened awareness of arthritis management, and the development of hospital and clinic infrastructure.

The arthritic therapeutic market is anticipated to experience substantial expansion over the upcoming years, with its size projected to reach $97.09 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This projected growth during the forecast period is fueled by several factors, including the emergence of novel biologics and focused treatments, a surge in the utilization of telemedicine and remote patient observation, the incorporation of digital health solutions, heightened investment in arthritis research and clinical studies, and the expansion of tailored medical strategies for arthritis. Furthermore, key trends expected within this period encompass a growing uptake of biologic and targeted therapies for arthritis, a heightened demand for individualized arthritis management programs, an increase in home-based physical therapy and rehabilitation services, the broadening of online pharmacies and digital distribution networks, and a reinforced emphasis on early detection and preventive care for arthritis.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19297&type=smp

What Key Drivers Are Fueling The Growth Of The Arthritic Therapeutic Market?

The rising occurrence of arthritis is projected to drive the expansion of the arthritic therapeutic market in the future. Arthritis encompasses over 100 conditions, primarily defined by joint discomfort and swelling. The frequency of arthritis is escalating, attributable to an aging populace, higher obesity levels, and lifestyle elements that exacerbate joint strain and inflammation. Treatments for arthritis work to ease symptoms, diminish inflammation, and enhance joint functionality, thereby improving the general quality of life for individuals impacted. For example, a report from June 2024, released by the Australian Institute of Health and Welfare, an Australia-based government body, indicated that around 514,000 individuals (2.0% of the population) were afflicted with rheumatoid arthritis in 2022. Rheumatoid arthritis constituted 2.0% of the overall disease burden and accounted for 16% of the complete burden for all musculoskeletal conditions during 2023. Consequently, the rising prevalence of arthritis is fueling the expansion of the arthritic therapeutic market.

Which Segment Categories Are Included In The Arthritic Therapeutic Market Segment Analysis?

The arthritic therapeutic market covered in this report is segmented –

1) By Drug Class: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Type: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout, Other Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab

2) By Interleukin Inhibitors: Interleukin-6 (IL-6) Inhibitors, Interleukin-1 (IL-1) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors

3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam

4) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

5) By Xanthine Oxidase Inhibitors: Allopurinol, Febuxostat

6) By Other Drug Classes: Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic DMARDs, Topical Analgesics, Opioid Pain Medications

What Trends Are Influencing The Arthritic Therapeutic Market?

Leading companies in the arthritis therapeutic market are concentrating on developing innovative solutions, such as biosimilar monoclonal antibody-based treatments, to boost treatment efficacy and cut costs. These biosimilar monoclonal antibody-based therapies are treatments designed to closely replicate and mimic the effectiveness of original monoclonal antibodies, providing similar therapeutic benefits at a potentially lower cost. For instance, in May 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, launched TOFIDENCE, an intravenous biosimilar monoclonal antibody formulation based on ACTEMRA. TOFIDENCE (tocilizumab-bavi) has been developed to be a biosimilar to the reference drug ACTEMRA and is approved for treating moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Who Are The Active Companies Shaping The Arthritic Therapeutic Market?

Major companies operating in the arthritic therapeutic market are Pfizer Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Pharma AB, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Zimmer Biomet Holdings Inc., UCB Pharma S.A., Incyte Corporation, Celltrion Inc., Mallinckrodt Pharmaceuticals, Genentech Inc., Anika Therapeutics Inc., Medac GmbH

Get The Full Arthritic Therapeutic Market Report:

https://www.thebusinessresearchcompany.com/report/arthritic-therapeutic-global-market-report

Which Region Is The Leading Market For The Arthritic Therapeutic Market?

North America was the largest region in the arthritic therapeutic market in 2025. The regions covered in the arthritic therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Arthritic Therapeutic Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/arthritic-therapeutic-global-market-report

Browse Through More Reports Similar to the Global Arthritic Therapeutic Market 2026, By The Business Research Company

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Glycomic Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795